Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)
Archiv der Pharmazie · 2025-01 · 358 (1)
DOI: 10.1002/ardp.202400163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 19.01.2025. Verfasst von Moeun Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents, Pyrimidines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), Korean government (MSIT), Ministry of Education of Korea.
Abstract (Originalsprache)
Cancer, the second leading cause of death globally, causes a significant threat to life. Despite advancements in the treatment of cancer, persistent challenges include severe side effects and the emergence of acquired drug resistance. Additionally, many traditional chemotherapy drugs show restricted efficacy and high toxicity, primarily attributed to their lack of selectivity. Thus, the development of drugs targeting protein kinases has emerged as a noteworthy priority for addressing human cancers. Medicinal chemists have shown considerable interest in the development of dual drug candidates as a strategy to create medicines that are safer, more efficient, and cost‐effective. Furthermore, the Food and Drug Administration (FDA) has approved several dual‐target drugs for anticancer treatment, emphasizing their lower risks of drug interactions and improved pharmacokinetics and safety profiles. This review focuses on the synthetic efforts, design strategies, and structure–activity relationship of the pyrimidine scaffold‐based dual kinase inhibitors developed with anticancer potential within the recent 6 years (2018‒2023). Collectively, these strategies are expected to offer fresh perspectives on the future directions of pyrimidine‐based dual‐target kinase drug design, potentially advancing cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul, Republic of Korea.
- Department of Chemistry, School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan.
- Biotechnology & Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni, suef, Egypt.
- Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Förderung
- National Research Foundation of Korea (NRF)
- Korean government (MSIT)
- Ministry of Education of Korea
Zitieren
APA
Song, M., Elkamhawy, A., Noh, W., Abdelazem, A. Z., Park, Y., Sivaraman, A., Bertleuova, A., Atef, D., & Lee, K. (2025). Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023). Archiv der Pharmazie, 358(1). https://doi.org/10.1002/ardp.202400163
Vancouver
Song M, Elkamhawy A, Noh W, Abdelazem AZ, Park Y, Sivaraman A, et al. Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023). Archiv der Pharmazie. 2025;358(1). doi:10.1002/ardp.202400163
BibTeX
@article{Song2025,
author = {Song, Moeun and Elkamhawy, Ahmed and Noh, Woojeong and Abdelazem, Ahmed Z and Park, Younggeun and Sivaraman, Aneesh and Bertleuova, Arailym and Atef, Dalia and Lee, Kyeong},
title = {Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {1},
doi = {10.1002/ardp.202400163}
}
EUVIMED